Cardona S, Tsegka K, Pasquel FJ, et al. - Researchers performed a double‐blinded, placebo‐control trial to ascertain if treatment with sitagliptin, beginning before surgery and continued during the hospital stay, can prevent and lessen the severity of perioperative hyperglycaemia in patients with type 2 diabetes undergoing coronary artery bypass graft (CABG) surgery. Adults with type 2 diabetes were randomly assigned to obtain sitagliptin or matching placebo beginning one day prior to surgery and continued during the hospital stay. One hundred eighty-two candidates randomised to receive sitagliptin or placebo (91 per group, age 64 ± 9 years, HbA1C: 7∙6 ± 1∙5%, and diabetes duration: 10 ± 9 years) were included. Sitagliptin administration prior to surgery and during the hospital stay did not prevent perioperative hyperglycaemia or complications following CABG. After transition to regular floors, sitagliptin therapy was correlated with lower mean daily insulin requirements.